Category Archives: Uncategorized

Indian Civil Society letter on TB Declaration negotiations -UN High Level Meeting

To, Mr. Narendra Modi, Prime Minister of India Mr. J. P. Nadda, Health Minister Ms. Sushma Swaraj, Foreign Minister Mr. Suresh Prabhu, Commerce Minister Date: 31st July 2018 Sub: Asking India to support TRIPS flexibilities in UN High Level Meeting on TB … Continue reading

Posted in Access to Medecines, Delinkage, R&D, TRIPS, TRIPS flexibilities, Tuberculosis (TB), Uncategorized | Leave a comment

Study published in BMJ shows that expenditure on medicines constitutes the single largest component of the total Out of Pocket payments by households

Thirty-eight million people slipped into poverty owing to expenses on medicines in year 2011-12. Just for perspective, poverty line in rural India is USD 11.82 a month, and for urban India it is calculated at 14.48 a month. Click here … Continue reading

Posted in Uncategorized | Leave a comment

The switch from patents to state-dependent prizes for technological innovation

by Hwan C. Lin, Journal of Macroeconomics Volume 50, December 2016, Pages 193-223 Highlights •Examine the intertemporal bounty (IB) system as an alternative to patents. •The IB system rewards innovation with a bounty claim to state-dependent prizes (called “intertemporal bounties”) over time. … Continue reading

Posted in Innovation, Patent, Patent examination system, Uncategorized | Leave a comment

The problem with high drug prices isn’t ‘foreign freeloading,’ it’s the patent system

by Tahir Amin, CNBC | June 27, 2018 One in four Americans are unable to fill prescriptions due to high prices. Today’s drug patent monopolies are stronger than at any point in the last century, raising prescription prices. Until the … Continue reading

Posted in Evergreening, Patent, Patent examination system, Patent Opposition, Uncategorized | Leave a comment

Patient Advocacy Successes in Fight for Medicines

by Fran Quigley, Health & Human Rights Journal | June 26, 2018 Access to essential medicines is a well-established component of the human right to health, but it is a right that remains elusive for millions of people across the globe. The … Continue reading

Posted in Access to Medecines, Biologics/Biosimilars, Cancer, Hepatitis C, Uncategorized | Leave a comment

Transparency in drug pricing an important goal: Dutch health minister

By Rema Nagarajan, The Times of India | June 21, 2018 Netherlands health minister Bruno Bruins was in India recently to promote investments in life sciences and health with affordable healthcare being a key concern for both countries. Bruins spoke to the Times … Continue reading

Posted in Drug prices, Uncategorized | Leave a comment

Drug prices row: EU health chief hits back at Trump view that Europe is ‘free-loading’ on US innovation

Vytenis Andriukaitis calls ‘fake news’ on Trump drug price blame game. Tariffs on medicines – if ever proposed by the US – would be ‘a humanitarian tragedy’, he says by Éanna Kelly, Science Business Health commissioner Vytenis Andriukaitis has flatly rejected the … Continue reading

Posted in Drug prices, Uncategorized | Leave a comment